Tailored Therapy: Decision Making for Ovarian Cancer Treatment

A medical expert discusses treatment decision-making and modalities for ovarian cancer, including palliative care and hospice.

EP: 1.NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP: 2.NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

EP: 3.Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

EP: 4.MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Now Viewing

EP: 5.Tailored Therapy: Decision Making for Ovarian Cancer Treatment

EP: 6.Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

EP: 7.Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Related Videos

Related Content

Advertisement

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 18th 2025

Defining On-Treatment Remission in Plaque Psoriasis

Pearl Steinzor

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey

June 18th 2025

Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

Maggie L. Shaw

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.

Related Content

Advertisement

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 18th 2025

Defining On-Treatment Remission in Plaque Psoriasis

Pearl Steinzor

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey

June 18th 2025

Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

Maggie L. Shaw

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.